CordenPharma Ltd.

Unit 4, OC Commercial Park
Little Island, Cork
Phone:+ 353 21 242 7383
Fax:+ 353 21 43 53 58 9

Get Driving Directions:

Get Directions

Core Capabilities

  • Development and production of controlled substances
  • Development of small molecule APIs and advanced intermediates
  • Patented manufacturing processes
  • Expertise in supporting development, submission and management of regulatory files (ASMF, CEP) for contracted customers
CordenPharma Cork R&D Center Capacities

Facility Legacy

CordenPharma Cork R&D Center’s core competencies consist of small-scale cGMP custom synthesis and development capabilities combined with extensive R&D services and full regulatory support.

Formerly a facility of Cambrex Corporation, CordenPharma Cork R&D Center brings over 15 years of experience in developing and producing controlled substances, small molecule APIs, advanced intermediates and patented manufacturing processes to the CordenPharma full-service CMO platform.


  • 1974 – Set up as a new production site for APIs witih Boehringer Ingelheim Group
  • 1992 – Sold to private equity group and established its presence in generic API and custom manufacturing business
  • 1992-2009 Major experience and expertise in development, sale-up manufacture and registration of generic APIs
  • 1999 – Sold to Cambrex Corporation (US)
  • 2006 – Acquired by ICIG to become CordenPharma Cork Ltd
  • 2009 – Closed manufacturing facility and relocated R&D operations to state-of-the-art laboratories nearby